- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05355389
Cognitive-motor Telerehabilitation in MS (CoMoTeMS)
May 4, 2026 updated by: Universitair Ziekenhuis Brussel
Cognitive-motor Telerehabilitation in Multiple Sclerosis
The primary goal of this project is providing evidence that a home-based combined cognitive-motor training program improves cognition in persons with multiple sclerosis (MS), compared to single cognitive and motor rehabilitation.
Secondary goals are to assess the effects on walking performance and to identify the mechanisms of improvement and predictors of treatment response.
The main backbone of this project will be a randomized controlled two-centre clinical trial, in which an at-home computerised cognitive-motor rehabilitation program using telemedicine aimed at improving working memory in persons with MS will be evaluated.
Based on the information gathered during this trial, possible mechanisms of improvement will be identified by analysing anatomical and neurophysiological changes on structural MRI and resting-state and task-related EEG before and after rehabilitation.
Furthermore, factors that can predict treatment response to the rehabilitation program will be identified.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
90
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Delphine Van Laethem
- Phone Number: +32 2 629 10 45
- Email: Delphine.Van.Laethem@vub.be
Study Contact Backup
- Name: Guy Nagels
- Phone Number: +32 2 477 64 10
- Email: guy.nagels@vub.be
Study Locations
-
-
-
Brussels, Belgium
- Recruiting
- Universitair Ziekenhuis Brussel
-
Contact:
- Guy Nagels
-
Melsbroek, Belgium
- Recruiting
- National MS Center Melsbroek
-
Contact:
- Miguel D'Haeseleer
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Clinically definite multiple sclerosis (revised McDonald criteria 2017)
- Expanded Disability Status Scale (EDSS) below 6.0
- Digit span backwards z-score between [-3 and -0.5] standard deviations below the median of the normative values
- Age between 18 and 65
- Able to safely perform motor rehabilitation in the home situation (assessed by rehabilitation physician and/or occupational or physiotherapist)
Exclusion Criteria:
- Cognitive rehabilitation within six months before inclusion
- Inpatient multidisciplinary rehabilitation program within three months before inclusion or planned inpatient program during trial
- Start of or switch in immunomodulator treatment within three months before inclusion
- Less than one month post-exacerbation
- Major psychiatric or medical disorder that could influence cognitive functions
- Combined vision with optimal correction below 0.6 on Snellen Visual Acuity Test
- Unable or unwilling to undergo EEG or MRI
- Refusing informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cognitive-motor training group
|
For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used.
This is a computer-aided program with more than 30 modules focusing on different domains of cognition.
RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417).
Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory.
Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
Other Names:
For the motor treatment intervention a patient-tailored aerobic training program will be used.
Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session.
The training will be carried out individually at home, without therapist supervision.
All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer.
Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
|
|
Active Comparator: Cognitive training group
|
For the cognitive treatment intervention the widely used cognitive training program RehaCom will be used.
This is a computer-aided program with more than 30 modules focusing on different domains of cognition.
RehaCom has shown improvements in verbal learning, visuospatial memory, information processing speed, attention, executive functions, depression, fatigue and quality of life in PwMS (PMID 31927200, 28116167, 19825502, 23192417).
Patients will train on their home computer without direct therapist supervision, using three RehaCom modules that are focused on improving working memory.
Both patients in the combined intervention and the cognitive intervention group will be doing a 45-minute computer session respectively one and two days per week for a total of 12 weeks.
Other Names:
|
|
Active Comparator: Motor training group
|
For the motor treatment intervention a patient-tailored aerobic training program will be used.
Based on their baseline physical activity level patients can choose out of a number of aerobic activities of either mild, moderate or strenuous intensity, with a total training time of 90 minutes for the motor intervention group and 45 minutes for the combined intervention group, divided over at least two training sessions per week of at least 15 minutes per session.
The training will be carried out individually at home, without therapist supervision.
All physical activities will be logged using the sport watch equipped with a heart rate sensor and an accelerometer.
Training intensity will be assessed using the patient's heart rate and the Rating of Perceived Exertion scale.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Digit span backwards
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of working memory
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of cognition in MS
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in Corsi backwards
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of working memory
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in Expanded Disability Status Scale (EDSS)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of disability in MS
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in 6-Minute Walk Test (6MWT)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of walking performance
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in 25-Foot Walk Test (25FWT)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of walking performance
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in 9-Hole Peg Test (9HPT)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of upper extremity function
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
MRI T1 3D BRAVO scan
Time Frame: 0 weeks, 12 weeks, 24 weeks
|
Cortical volume, volumes of white matter and deep grey matter
|
0 weeks, 12 weeks, 24 weeks
|
|
MRI T2 FLAIR 3D Cube scan
Time Frame: 0 weeks, 12 weeks, 24 weeks
|
Lesion volume
|
0 weeks, 12 weeks, 24 weeks
|
|
Synthetic MRI
Time Frame: 0 weeks, 12 weeks, 24 weeks
|
Contrast weighted images based on measurements of tissue properties from a single acquisition
|
0 weeks, 12 weeks, 24 weeks
|
|
resting-state EEG
Time Frame: 0 weeks, 12 weeks
|
functional connectivity using graph theoretical measures
|
0 weeks, 12 weeks
|
|
task-related EEG - auditory oddball paradigm
Time Frame: 0 weeks, 12 weeks
|
functional connectivity using graph theoretical measures, event-related potentials
|
0 weeks, 12 weeks
|
|
task-related EEG - adjusted SDMT paradigm
Time Frame: 0 weeks, 12 weeks
|
functional connectivity using graph theoretical measures, event-related potentials
|
0 weeks, 12 weeks
|
|
task-related EEG - n-back paradigm
Time Frame: 0 weeks, 12 weeks
|
functional connectivity using graph theoretical measures, event-related potentials
|
0 weeks, 12 weeks
|
|
Diffusion weighted image (DWI)
Time Frame: 0 weeks, 12 weeks, 24 weeks
|
structural connectivity using graph theoretical measures; diffusion tensor image parameters
|
0 weeks, 12 weeks, 24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Hospital Anxiety and Depression Scale (HADS)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of anxiety and depression
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in Fatigue Scale for Motor and Cognitive functions (FSMC)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of fatigue in MS
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in Visual Analogue Scale (VAS)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
VAS on the impact of perceived cognitive symptoms on daily life
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in 36-Item Short Form Survey (SF-36)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of quality of life Only Dutch-speaking participants
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in Multiple Sclerosis Impact Scale-29 (MSIS-29)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of quality of life in MS Only Dutch-speaking participants
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in Multiple Sclerosis-59 (SEP-59)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of quality of life, combination of SF-36 and MS-specific questions Only French-speaking participants Of note, the French title of this questionnaire is Sclérose En Plaques-59.
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in Cognitive Leisure Activity Scale (CLAS)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of baseline cognitive activities
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
|
Change in Godin Leisure-Time Exercise Questionnaire (GLTEQ)
Time Frame: 0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Measure of baseline physical activities
|
0 weeks, 12 weeks, 24 weeks, 64 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Guy Nagels, Vrije Universiteit Brussel, Universitair Ziekenhuis Brussel
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2022
Primary Completion (Estimated)
August 31, 2027
Study Completion (Estimated)
August 31, 2027
Study Registration Dates
First Submitted
April 14, 2022
First Submitted That Met QC Criteria
April 25, 2022
First Posted (Actual)
May 2, 2022
Study Record Updates
Last Update Posted (Actual)
May 8, 2026
Last Update Submitted That Met QC Criteria
May 4, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Autoimmune Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Multiple Sclerosis
- Therapeutics
- Patient Care
- Health Services
- Health Care Facilities Workforce and Services
- Rehabilitation
- Aftercare
- Continuity of Patient Care
- Neurological Rehabilitation
- Cognitive Training
Other Study ID Numbers
- CoMoTeMS
- 1SD5322N (Other Grant/Funding Number: Fonds Wetenschappelijk Onderzoek (FWO))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Cognitive training
-
Science and Research Centre KoperAlbert Einstein College of Medicine; University of Primorska; Vrije Universiteit...CompletedEffects of Cognitive Intervention on Cognition, Mobility and Brain Electrocortical Activity (GIBKOP)Cognitive Impairment | Aging | Cognitive Decline | Motor Coordination or FunctionSlovenia
-
Hospital de Clinicas de Porto AlegreYale UniversityUnknownAttention-deficit/Hyperactivity Disorder.Brazil
-
Universidade Federal do Rio de JaneiroUnknown
-
Xuanwu Hospital, BeijingRecruitingMild Cognitive ImpairmentChina
-
Chang Gung Memorial HospitalRecruitingVirtual Reality | Community-dwelling ElderlyTaiwan
-
Fanfan ZhengEnrolling by invitationDiabetes Mellitus, Type 2 | Aging | CognitionChina
-
Fundació Sant Joan de DéuCompletedIndication for Modification of Patient Cognitive StatusSpain
-
Chiang Mai UniversityCompletedMild Cognitive ImpairmentThailand
-
Chang Gung Memorial HospitalRecruitingMCI | SCD | Virtual RealityTaiwan
-
University of California, San FranciscoCompletedSchizophrenia | PsychosisUnited States